BCRX vs GLAS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BCRX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BCRX and GLAS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BCRX and GLAS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases, with a near-total focus on hereditary angioedema (HAE), a genetic disorder that causes unpredictable and sometimes life-threatening swelling attacks. Its lead product is ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor approved to prevent HAE attacks, which competes against injectable and infused prophylaxis therapies. The company also markets RAPIVAB (peramivir) for influenza and, through its January 2026 acquisition of Astria Therapeutics, added navenibart (formerly STAR-0215), a long-acting injectable antibody in Phase 3 for HAE prophylaxis, plus an early-stage ocular program (avoralstat).

Full BCRX guide

Glass House Brands is a vertically integrated cannabis company headquartered in Long Beach, California, that reports across three segments: Wholesale Biomass (selling bulk cannabis flower and trim), Retail (its own dispensaries), and Cannabis-Related Consumer Packaged Goods (its branded products). Its defining asset is massive greenhouse cultivation capacity, anchored by a large SoCal Farm, that lets it grow cannabis at a low cost per pound relative to indoor growers. The strategy is scale and cost leadership: produce enormous volumes of biomass cheaply, sell into the California wholesale market, and layer higher-margin brands and retail on top. Wholesale biomass has recently made up the majority of revenue, and the company has been expanding planted acreage and building out additional greenhouse capacity.

Full GLAS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BCRX drivers: ORLADEYO revenue growth and operating leverage; Navenibart and the Astria pipeline bet.
• GLAS drivers: Low-cost greenhouse scale; Brands and retail as margin layers.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: BioCryst is a concentrated single-franchise story: the large majority of revenue comes from ORLADEYO, so any competitive share loss, pricing pressure, or safety signal would hit hard. For GLAS, the dominant risk is California wholesale cannabis pricing, which has been deeply depressed by oversupply and drove average selling prices and gross margin sharply lower, keeping the company unprofitable.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BCRX if you believe its drivers more; GLAS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BCRX and GLAS guides.

BCRX. BioCryst trades on the strength and durability of its ORLADEYO franchise rather than on GAAP earnings, since 2026 results were dominated by a roughly $698 million one-time non-cash acquired-IPR&D charge from the Astria deal that produced a large GAAP operating loss. On a non-GAAP basis the company reported operating profit and reaffirmed full-year revenue guidance. Because so much value sits in a single growing product plus a late-stage pipeline candidate, the market cap reflects expectations for peak ORLADEYO sales and navenibart success as much as trailing figures.

GLAS. These are qualitative, approximate framings tied to the asOf date, not precise live figures; confirm current numbers before acting. Because Glass House is unprofitable and its results hinge on volatile California wholesale prices and uncertain federal policy, traditional earnings multiples say little. What matters most is the direction of selling prices, production volume, cost per pound, the mix shift toward retail and brands, and any movement on rescheduling. This is a speculative, catalyst-driven cannabis stock rather than a value-of-current-earnings play.

Headline figures (approximate, JUNE 2026): BCRX shows revenue (ttm) ~$630M, q1 2026 total revenue ~$156M, q1 2026 orladeyo revenue ~$148M (up ~11% YoY), 2026 orladeyo guidance ~$625M to $645M; GLAS shows revenue trend Roughly $40.5 million in Q1 2026, down from about $44.8 million a year earlier; full-year 2026 guidance around $235 to $245 million. Wholesale biomass has been the majority of revenue. Approximate; verify live., profitability Unprofitable. Gross margin compressed to around 25% in Q1 2026 (versus roughly 45% a year earlier) and net losses deepened as selling prices fell and costs rose. Approximate; verify live., unit economics Average selling price around $171 per pound in Q1 2026, down from roughly $193 a year earlier, reflecting weak California wholesale pricing. Biomass production guided near 1,000,000 pounds for 2026. Approximate; verify live., balance sheet A scaling grower funding greenhouse expansion while losing money, so cash generation, debt, and potential dilution are worth watching closely. Verify current figures..

BCRX and GLAS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BCRX and GLAS exposure against your real portfolio. It is not an investment adviser.